Miami Team Spots Hidden Cancer With Breakthrough Scan

For families facing multiple myeloma, few things bring more anxiety than the fear that cancer still lingers in the shadows after grueling treatment. A pioneering medical breakthrough is now illuminating those invisible threats and offering patients true peace of mind.

Researchers at the University of Miami Miller School of Medicine have developed a targeted imaging technology that catches hidden cancer cells when standard hospital scans show nothing. Their phase 2 clinical trial proves that this precision method can radically reshape how doctors monitor and eliminate disease.

Multiple myeloma strikes more than 36,000 Americans each year, quietly taking root inside bone marrow. For decades, oncologists have relied on standard glucose scans to track the condition, assuming tumor cells always devour sugar faster than normal tissue.

In multiple myeloma, however, cancer cells often consume the exact same amount of sugar as healthy neighbors. This cellular disguise means standard scans miss residual tumors in up to 40 percent of cases.

To tear away that disguise, lead researcher Dr. C. Ola Landgren and his team created an innovative tool called immunoPET. Instead of tracking sugar, the team designed specialized antibodies that seek out a distinct surface protein called CD38 found directly on myeloma cells.

The team tested the approach across 60 patients who received both standard scans and the new antibody scan. In more than 10 percent of participants, the antibody scan lit up active tumors that conventional tests completely overlooked.

The discovery brought immediate, life-changing answers to patients in the trial. One individual lived with persistent, unexplained back pain despite spotless routine bloodwork, until the scan pinpointed hidden spinal lesions that doctors promptly treated.

In another remarkable case, standard tests showed zero evidence of disease, but the new scan uncovered nearly 100 cancer sites throughout the body. Spotting those hidden clusters allowed physicians to adjust therapy immediately, halting the cancer before it could spread further.

The Ripple Effect

This discovery marks a vital leap forward toward developing reliable cures for blood cancers. Combining high-precision scans with traditional biopsies ensures oncologists never leave a single rogue cell behind after therapy concludes.

The Miami team is already engineering smaller antibody fragments to speed up delivery, aiming to offer same-day testing for routine clinic visits. Clearer scans mean faster interventions, fewer relapses, and brighter tomorrows for thousands of cancer survivors.

Every hidden cancer cell brought into the light brings humanity one step closer to curing multiple myeloma for good.